India's richest state bans guru's 'spurious' coronavirus treatment

South Asia

Reuters
25 June, 2020, 09:25 pm
Last modified: 25 June, 2020, 09:27 pm
Baba Ramdev, co-founder of Patanjali and a household name in India, launched Coronil to much fanfare on Tuesday, but hit a roadblock when New Delhi and some state governments expressed scepticism

India's richest state on Thursday banned a "spurious" coronavirus treatment manufactured by a company founded by popular yoga guru, which he says has a 100 percent record in curing patients.

Baba Ramdev, co-founder of Patanjali and a household name in India, launched Coronil to much fanfare on Tuesday, but hit a roadblock when New Delhi and some state governments expressed scepticism.

The western state of Maharashtra banned the drug.

"Maharashtra won't allow the sale of spurious medicine," state minister Anil Deshmukh tweeted on Thursday, adding authorities would probe whether any clinical trials had been run.

Deshmukh could not be reached for a comment. Patanjali did not immediately respond to an email from Reuters seeking comment.

Hours after its launch, India's federal government asked Patanjali to provide details about Coronil, trials and sample size and asked the company to stop advertising the product until it had been approved.

Ramdev, who is seen as a supporter of Indian Prime Minister Narendra Modi, said at the launch that the medicine consisted of ancient Ayurvedic ingredients that boost immunity and had a 100 percent cure rate.

India reported a record increase of nearly 17,000 coronavirus infections on Thursday, taking the total to 473,105 with 14,894 deaths.

Maharashtra, home to India's financial hub of Mumbai, has been the hardest hit by the pandemic, accounting for more than 25 percent of cases.

The state reported some 3,890 new infections on Thursday, taking its tally up to 142,900 cases. It has recorded 6,739 deaths.

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.